Compare Fulford India with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs ASTRAZENECA PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA ASTRAZENECA PHARMA FULFORD INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 398.8 76.3 522.3% View Chart
P/BV x 6.2 21.5 28.9% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 FULFORD INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
ASTRAZENECA PHARMA
Mar-18
FULFORD INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs9421,278 73.7%   
Low Rs450883 51.0%   
Sales per share (Unadj.) Rs691.4228.4 302.7%  
Earnings per share (Unadj.) Rs11.510.4 110.6%  
Cash flow per share (Unadj.) Rs15.416.3 94.5%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs380.098.8 384.7%  
Shares outstanding (eoy) m3.9025.00 15.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.04.7 21.3%   
Avg P/E ratio x60.7104.2 58.3%  
P/CF ratio (eoy) x45.366.4 68.2%  
Price / Book Value ratio x1.810.9 16.7%  
Dividend payout %17.40-   
Avg Mkt Cap Rs m2,71427,008 10.1%   
No. of employees `0000.41.4 32.7%   
Total wages/salary Rs m5051,535 32.9%   
Avg. sales/employee Rs Th6,073.04,210.9 144.2%   
Avg. wages/employee Rs Th1,137.41,132.2 100.5%   
Avg. net profit/employee Rs Th100.7191.1 52.7%   
INCOME DATA
Net Sales Rs m2,6965,710 47.2%  
Other income Rs m125123 102.4%   
Total revenues Rs m2,8225,833 48.4%   
Gross profit Rs m-46463 -10.0%  
Depreciation Rs m15147 10.3%   
Interest Rs m100-   
Profit before tax Rs m54438 12.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m10179 5.4%   
Profit after tax Rs m45259 17.3%  
Gross profit margin %-1.78.1 -21.2%  
Effective tax rate %17.740.8 43.3%   
Net profit margin %1.74.5 36.5%  
BALANCE SHEET DATA
Current assets Rs m1,7383,209 54.2%   
Current liabilities Rs m5452,070 26.3%   
Net working cap to sales %44.320.0 221.8%  
Current ratio x3.21.6 205.8%  
Inventory Days Days4872 67.0%  
Debtors Days Days435 12.3%  
Net fixed assets Rs m12790 1.5%   
Share capital Rs m3950 78.0%   
"Free" reserves Rs m1,4432,419 59.6%   
Net worth Rs m1,4822,469 60.0%   
Long term debt Rs m00-   
Total assets Rs m2,0774,605 45.1%  
Interest coverage x6.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.31.2 104.7%   
Return on assets %2.65.6 46.4%  
Return on equity %3.010.5 28.7%  
Return on capital %4.317.7 24.3%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m17300 5.7%   
Fx outflow Rs m6732,015 33.4%   
Net fx Rs m-656-1,715 38.2%   
CASH FLOW
From Operations Rs m9088 102.4%  
From Investments Rs m105-94 -111.8%  
From Financial Activity Rs m-14NA-  
Net Cashflow Rs m181-6 -3,166.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 3.8 0.3 1,266.7%  
FIIs % 0.1 15.7 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 9.1 233.0%  
Shareholders   4,783 12,856 37.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare FULFORD INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS